KIYATEC receives additional financing for ongoing clinical studies

Written by   in 

KIYATEC, Inc., a South Carolina startup based on technology developed at Clemson University, has recently announced the $3 million initial closing of the company’s B2 financing round. In addition to the funding, KIYATEC has welcomed LabCorp as a new investor. LabCorp’s investment in KIYATEC is of particular significance because of their expertise in oncology and their preclinical and clinical development strengths. With these new developments, KIYATEC is poised to sharpen their ongoing clinical study, 3D-PREDICT.

An innovator in cancer treatment, KIYATEC works to change the future of cancer care through predicting how cancer patients respond to drug therapies. In the past few months, KIYATEC has gained significant momentum. They have demonstrated leading capabilities in modeling and prediction response to immune-oncology therapies at the 110th Annual Meeting of the American Association for Cancer Research (AACR). On April 10th, they were one of 20 startups chosen to participate in the 2019 University Innovation & Entrepreneurship Showcase. Most notably, in 2019 KIYATEC has added three clinical sites to its 3D-PREDICT study and expects to add additional sites soon. 

For more information on KIYATEC, click here

Clemson University spin-off, Kiyatec, LLC, participates in Innovation and Entrepreneurship Showcase on Capitol Hill

KIYATEC, Inc., a Clemson-based company, was selected to participate in The University Innovation and Entrepreneurship Showcase that took place on Capitol Hill on April 10. The event, hosted by the Association of Public and Land-grant Universities (APLU) and the Association of American Universities (AAU), recognizes the impact that federally-funded research has on driving entrepreneurship and innovation. 

KIYATEC’S innovative research on 3D cell culture began at Clemson University. Their ex vivo 3D cell culture technology allows accurate modeling and prediction of cancer patient response to drug therapies. KIYATEC’S validated process uses cancer cells taken from patients via surgical or biopsy tissues to create a life-like replication in order to determine what treatments the patient will respond to prior to beginning the treatment.  

Startups for the showcase were chosen based on the level of student engagement in the startup, the strength of the technology the startup produces, and its relationship to research. For more information on KIYATEC, click here

Recovr, Inc. receives SC Launch, Inc. investment from SCRA

 Recovr, Inc., a Clemson-based company, has worked to provide alternative therapy options for post-stroke survivors who suffer from arm-impairment. In 2013, Recovr was founded by Clemson researchers who licensed their initial stroke research done at Clemson and MUSC through the Clemson University Research Foundation (CURF). Led by Austen Hayes, a member of the original development team, as the CEO, their current product, the Recovr Rehabilitation System (RRS), has now expanded to support therapy of a wide range of physical and neurological conditions while also capturing and automatically documenting a patient’s progress and compliance with their rehabilitation program. 

Recently, Recovr has received an investment from SC Launch, Inc. of the South Carolina Research Authority (SCRA). Totaling $200,000, the investment will allow Recovr to expand their sales and fund further development of Recovr’s Telerehabilitation Platform that will enable providers to enhance outcomes and decrease costs with home-based rehabilitation. 

For more information on Recovr and the SC Launch investment, click here.